Whanin Pharm (016580) — Cash Flow-to-Debt Ratio
Whanin Pharm (016580) has a Cash Flow-to-Debt Ratio of 0.04x as of December 2025, meaning its operating cash flow of ₩2.38 Billion could theoretically repay 0% of its total liabilities (₩57.88 Billion) in one year. Explore investment intensity of Whanin Pharm to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Whanin Pharm Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for Whanin Pharm across 13 annual periods. Also explore total assets of Whanin Pharm for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Whanin Pharm (2009–2025)
Year-by-year debt coverage analysis for Whanin Pharm. For market capitalisation and broader financial context, see 016580 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | ₩9.04 Billion | ₩57.88 Billion | ▼ -63.2% |
| 2024 | 0.42x | ₩20.69 Billion | ₩48.70 Billion | ▼ -21.2% |
| 2023 | 0.54x | ₩23.20 Billion | ₩43.02 Billion | ▲ +13.4% |
| 2022 | 0.48x | ₩16.85 Billion | ₩35.45 Billion | ▼ -51.6% |
| 2021 | 0.98x | ₩35.32 Billion | ₩35.96 Billion | ▲ +42.2% |
| 2020 | 0.69x | ₩22.75 Billion | ₩32.96 Billion | ▼ -15.1% |
| 2019 | 0.81x | ₩24.73 Billion | ₩30.42 Billion | ▲ +30.9% |
| 2018 | 0.62x | ₩17.45 Billion | ₩28.10 Billion | ▼ -16.0% |
| 2017 | 0.74x | ₩23.48 Billion | ₩31.75 Billion | ▼ -13.0% |
| 2016 | 0.85x | ₩19.82 Billion | ₩23.31 Billion | ▼ -23.9% |
| 2012 | 1.12x | ₩21.11 Billion | ₩18.90 Billion | ▲ +20.1% |
| 2011 | 0.93x | ₩15.12 Billion | ₩16.25 Billion | ▼ -47.5% |
| 2009 | 1.77x | ₩18.61 Billion | ₩10.51 Billion | — |